<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732939</url>
  </required_header>
  <id_info>
    <org_study_id>307BCNeo-01</org_study_id>
    <nct_id>NCT01732939</nct_id>
  </id_info>
  <brief_title>Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Affiliated to Military Medical Science, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Affiliated to Military Medical Science, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for&#xD;
      invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines plus&#xD;
      taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hope to get preliminary results for the breast cancer patients who are&#xD;
      given different neoadjuvant chemothetapy regimens. The patients are randomized two&#xD;
      chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is&#xD;
      anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for&#xD;
      3-4 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate, safety</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AT</arm_group_label>
    <description>Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-NP</arm_group_label>
    <description>docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        diaganosis of invasive breast cancer, tumor size &gt; 2.0cm by MRI or ultrasound or clinical&#xD;
        examination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of invasive ductal or lobular breast cancer.&#xD;
&#xD;
          -  Previously untreated (no chemotherapy or hormonal therapy or radiation therapy)&#xD;
             invasive breast cancer.&#xD;
&#xD;
          -  no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive)&#xD;
&#xD;
          -  Performance Status ECOG &lt;2&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Tumor &gt; 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky&#xD;
             &gt;50%&#xD;
&#xD;
          -  Lab test :&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,500/mm3&#xD;
&#xD;
                    -  Total Bilirubin ≤ 2×ULN&#xD;
&#xD;
                    -  AST and ALT ≤ 2.5×ULN&#xD;
&#xD;
               -  serum creatinine ≤ 1.5×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding patients are excluded&#xD;
&#xD;
          -  stage Ⅳ breast cancer&#xD;
&#xD;
          -  History of non-breast malignancies within the 5 years prior to study entry, except for&#xD;
             the following: carcinoma in situ of the cervix, carcinoma in situ of the&#xD;
             colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin&#xD;
&#xD;
          -  uncontrolled cardiac disease&#xD;
&#xD;
          -  Active infection or chronic infection requiring chronic suppressive antibiotics&#xD;
&#xD;
          -  History of hypersensitivity reaction to investigating drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Affiliated Military Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital affiliated academy military medical science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Wang, MD</last_name>
      <phone>8610-66947430</phone>
    </contact>
    <contact_backup>
      <last_name>Shaohua ZHANG, MD</last_name>
      <phone>8610-66947173</phone>
    </contact_backup>
    <investigator>
      <last_name>Zefei Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>November 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2012</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

